Kamada Licenses Alvotech Biosimilars In Israel
First Launch, Teriparatide, Is Slated For 2022
Israel’s Kamada has struck a licensing deal with Alvotech that gives it rights to several of the firm’s biosimilars in its domestic market. The first launch, of the teriparatide biosimilar co-developed with Pfenex, is planned for 2022.
You may also be interested in...
Alvotech and Stada have struck a deal that will give Stada exclusive rights to sell seven Alvotech biosimilars “in all key European markets” as well as certain other territories.
Alvotech has struck an investment deal worth $45m with Yas Holding that will give Yas a 2.5% stake in the business, as well as rights to sell three Alvotech biosimilars in the MENA region.
Alvogen has signed marketing deals with local firms in Canada, Israel and South Korea for the teriparatide drug it has licensed from Pfenex. In the US, Pfenex has just completed a human factors study it feels should support a therapeutic equivalence rating for its Forteo rival.